Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Coeptis Therapeutics' Phase 1 Trials Of DVX201 For Relapsed/Refractory Acute Myeloid Leukemia Or High-risk Myelodysplastic Syndrome And Hospitalized Covid-19 Patients Showed No Dose-limiting Toxicities, Cytokine Release Syndrome Or Infusion Toxicities

Author: Benzinga Newsdesk | September 14, 2023 07:35am

Coeptis Expects To Report Topline Safety And Efficacy Data From The Full Patient Population In Q1 Of 2024

Posted In: COEP